Zonegran - Drug Monograph

Introduction

Zonegran (zonisamide) is a sulfonamide-class antiepileptic drug (AED) used primarily as adjunctive therapy for refractory partial-onset seizures in adults. It is distinguished from many older anticonvulsants by a long elimination half-life permitting once-daily dosing and a multimodal mechanism of action. Zonisamide is also used off-label for migraine prophylaxis, essential tremor, and weight management in selected contexts, reflecting its broader neuropharmacologic profile.

Drug Class and Overview

• Class: Anticonvulsant/antiepileptic; chemically a benzisoxazole sulfonamide derivative.
• Related agents: Acetazolamide and topiramate share sulfonamide-related structural features and carbonic anhydrase inhibition; however, zonisamide's primary anticonvulsant activity is mediated through ion channel modulation rather than carbonic anhydrase inhibition alone.
• Distinguishing features: Long half-life (~60+ hours), broad-spectrum activity in animal seizure models, and clinically relevant effects on weight (often weight loss) and cognition.

Mechanism of Action

Zonisamide has multiple complementary mechanisms:

1. Blockade of voltage-gated sodium channels — reduces sustained repetitive neuronal firing by prolonging the inactivated state.
2. Blockade of T-type calcium channels — relevant for absence and generalized seizure suppression.
3. Facilitation of GABA-mediated neurotransmission — enhances inhibitory synaptic activity.
4. Weak inhibition of carbonic anhydrase — contributes to metabolic acidosis and paresthesias but is not the primary anticonvulsant mechanism.

The combination of sodium and calcium channel effects plus GABAergic activity underlies its broad-spectrum anticonvulsant profile.

Indications

• FDA-approved: Adjunctive therapy in the treatment of partial-onset (focal) seizures in adults (≥18 years).
• Off-label / evidence-supported uses (commonly cited in clinical references):
• Migraine prophylaxis
• Essential tremor
• Bipolar disorder (adjunctive)
• Weight loss adjunct (in selected patients; not FDA-approved for this indication)

Dosage and Administration

• Initial adult dose: 100 mg orally once daily.
• Titration: May increase to 200 mg/day after 2 weeks; further increases to 300 mg/day and 400 mg/day can be made at intervals of ≥2 weeks as needed and tolerated.
• Maximum dose: Up to 600 mg/day has been studied; many clinicians cap at 400 mg/day due to diminishing benefit and increased adverse effects.
• Renal impairment: Use with caution; slower titration recommended in CrCl <50 mL/min.
• Hepatic impairment: Use with caution; no formal dose adjustment established.
• Pediatric: Not FDA-approved for epilepsy in children in the United States; used in some countries for pediatric epilepsy with weight-based dosing.
• Geriatric: Start low and titrate slowly; monitor for sedation, falls, and cognitive effects.
• Pregnancy: Category C (per older FDA labeling); generally avoid in pregnancy unless benefit outweighs risk; enroll pregnant patients in the North American Antiepileptic Drug Pregnancy Registry if used.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed orally; Tmax ~2–6 hours. Food does not substantially alter absorption.
• Distribution: Approximately 40–50% protein-bound; Vd ~1.0–1.5 L/kg.
• Metabolism: Primarily hepatic via CYP3A4 (with minor contributions from CYP2D6 and CYP2C19); undergoes N-acetylation and reductive cleavage.
• Elimination: Renal excretion of parent drug and metabolites; ~62% recovered in urine.
• Half-life: ~63 hours in plasma (one of the longest among AEDs), permitting once-daily dosing.

Contraindications

• Known hypersensitivity to zonisamide, sulfonamides, or any component of the formulation.

Warnings and Precautions

• Serious dermatologic reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported; discontinue at first sign of rash unless clearly unrelated.
• Sulfonamide cross-reactivity: Risk of hypersensitivity reactions in patients with sulfa allergy.
• Hematologic reactions: Aplastic anemia, agranulocytosis, and pancytopenia reported rarely; discontinue if significant cytopenias develop.
• Metabolic acidosis: Hyperchloremic, non-anion gap metabolic acidosis due to carbonic anhydrase inhibition; monitor serum bicarbonate, especially with renal disease, severe respiratory disease, or concurrent carbonic anhydrase inhibitors.
• Nephrolithiasis: Increased risk of kidney stones; encourage adequate hydration.
• Oligohydrosis and hyperthermia: Reduced sweating and heat intolerance reported, predominantly in pediatric patients; caution in hot environments.
• Suicidal ideation and behavior: AEDs carry an FDA-class warning for increased risk of suicidal thoughts; monitor mood and behavior.
• Cognitive and psychomotor impairment: Somnolence, confusion, word-finding difficulty, and impaired concentration may occur, particularly during titration.
• Hyperammonemia with concomitant valproate: Reported; monitor ammonia if used together.

Drug Interactions

• CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampin): Decrease zonisamide plasma concentrations; may require dose adjustment.
• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase zonisamide levels.
• Other carbonic anhydrase inhibitors (e.g., acetazolamide, topiramate): Additive risk of metabolic acidosis and nephrolithiasis.
• Valproate: Increased risk of hyperammonemia and encephalopathy.
• CNS depressants (alcohol, opioids, benzodiazepines, other sedating AEDs): Additive sedation and cognitive impairment.
• Oral contraceptives: No clinically significant interaction reported.

Adverse Effects

Common (≥10%):

• Somnolence
• Dizziness
• Anorexia
• Headache
• Nausea
• Fatigue
• Cognitive impairment (word-finding difficulty, impaired concentration)

Less common:

• Weight loss
• Ataxia
• Paresthesias
• Diplopia
• Tremor

Serious/rare:

• Stevens-Johnson syndrome / TEN
• Aplastic anemia, agranulocytosis
• Metabolic acidosis
• Nephrolithiasis
• Heat stroke / oligohydrosis
• Suicidal ideation
• Status epilepticus (on withdrawal)

Monitoring Parameters

• Serum bicarbonate: Baseline and periodically (every 3–6 months) due to risk of metabolic acidosis.
• Renal function: Baseline and periodically; assess hydration status.
• Complete blood count (CBC): Baseline and as clinically indicated.
• Ammonia level: If co-administered with valproate or if encephalopathy symptoms develop.
• Skin examination: At each visit; counsel patients to report rash immediately.
• Mood and suicidality: Screen at baseline and follow-up visits.
• Seizure frequency and tolerability: Standard efficacy and safety monitoring.
• Body weight: Useful given common weight loss effect.

Patient Education

• Take once daily with or without food; swallow capsules whole.
• Do not stop abruptly — sudden discontinuation can precipitate seizures or status epilepticus.
• Drink adequate fluids to reduce the risk of kidney stones and heat-related complications.
• Report any skin rash, fever, mouth sores, easy bruising, or unusual bleeding immediately.
• Avoid driving or operating heavy machinery until you know how the medication affects you.
• Be aware of possible drowsiness, dizziness, and difficulty concentrating; alcohol may worsen these effects.
• Report new or worsening depression, suicidal thoughts, or unusual mood changes.
• Use effective contraception if of childbearing potential; discuss pregnancy planning with your clinician.

Clinical Pearls

1. Zonisamide's long half-life (~63 hours) allows once-daily dosing but also means steady state takes ~2 weeks — counsel patients that full effect may take time.
2. The combination of sodium channel blockade, T-type calcium channel blockade, and GABAergic effects makes zonisamide a useful broad-spectrum adjunct when first-line agents fail.
3. Weight loss is a notable side effect and may be beneficial in some patients but problematic in others; monitor BMI.
4. Always check serum bicarbonate — clinically silent metabolic acidosis is common due to carbonic anhydrase inhibition.
5. Avoid combining with other carbonic anhydrase inhibitors (topiramate, acetazolamide) when possible due to additive acidosis and stone risk.
6. Taper slowly over ≥2 weeks when discontinuing to avoid rebound seizures.

References

1. Eisai Inc. Zonegran (zonisamide) Capsules Prescribing Information. U.S. Food and Drug Administration.
2. U.S. Food and Drug Administration. Information for Healthcare Professionals: Suicidal Behavior and Ideation and Antiepileptic Drugs. FDA Drug Safety Communication.
3. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill.
4. Katzung BG, Vanderah TW, eds. Basic and Clinical Pharmacology. 15th ed. McGraw-Hill.
5. Lexicomp Online. Zonisamide Drug Information. Wolters Kluwer Clinical Drug Information.
6. World Health Organization. Model List of Essential Medicines — Antiepileptic Medicines. WHO.
7. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia.
8. American Academy of Neurology. Practice Guidelines for the Pharmacologic Treatment of Epilepsy. AAN.
9. Micromedex (IBM Watson Health). Zonisamide — Drug Summary. IBM Corporation.
10. Clinical Pharmacology. Zonisamide Monograph. Elsevier/Gold Standard.